These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37408186)

  • 41. MG132 Induces Progerin Clearance and Improves Disease Phenotypes in HGPS-like Patients' Cells.
    Harhouri K; Cau P; Casey F; Guedenon KM; Doubaj Y; Van Maldergem L; Mejia-Baltodano G; Bartoli C; De Sandre-Giovannoli A; Lévy N
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progerin-Induced Replication Stress Facilitates Premature Senescence in Hutchinson-Gilford Progeria Syndrome.
    Wheaton K; Campuzano D; Ma W; Sheinis M; Ho B; Brown GW; Benchimol S
    Mol Cell Biol; 2017 Jul; 37(14):. PubMed ID: 28483909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential stem cell aging kinetics in Hutchinson-Gilford progeria syndrome and Werner syndrome.
    Wu Z; Zhang W; Song M; Wang W; Wei G; Li W; Lei J; Huang Y; Sang Y; Chan P; Chen C; Qu J; Suzuki K; Belmonte JCI; Liu GH
    Protein Cell; 2018 Apr; 9(4):333-350. PubMed ID: 29476423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.
    Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG
    Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
    Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Qiao X; Fong LG; Young SG
    Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS.
    Gete YG; Koblan LW; Mao X; Trappio M; Mahadik B; Fisher JP; Liu DR; Cao K
    Aging Cell; 2021 Jul; 20(7):e13388. PubMed ID: 34086398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
    Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
    Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Embryonic senescence and laminopathies in a progeroid zebrafish model.
    Koshimizu E; Imamura S; Qi J; Toure J; Valdez DM; Carr CE; Hanai J; Kishi S
    PLoS One; 2011 Mar; 6(3):e17688. PubMed ID: 21479207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
    Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
    Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells.
    Aveleira CA; Ferreira-Marques M; Cortes L; Valero J; Pereira D; Pereira de Almeida L; Cavadas C
    J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1073-1078. PubMed ID: 32012215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone dysplasia in Hutchinson-Gilford progeria syndrome is associated with dysregulated differentiation and function of bone cell populations.
    Cabral WA; Stephan C; Terajima M; Thaivalappil AA; Blanchard O; Tavarez UL; Narisu N; Yan T; Wincovitch SM; Taga Y; Yamauchi M; Kozloff KM; Erdos MR; Collins FS
    Aging Cell; 2023 Sep; 22(9):e13903. PubMed ID: 37365004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of the Hutchinson-Gilford Progeria Mutation Leads to Aberrant Dentin Formation.
    Choi H; Kim TH; Jeong JK; Strandgren C; Eriksson M; Cho ES
    Sci Rep; 2018 Oct; 8(1):15368. PubMed ID: 30337599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells.
    Egesipe AL; Blondel S; Lo Cicero A; Jaskowiak AL; Navarro C; Sandre-Giovannoli A; Levy N; Peschanski M; Nissan X
    NPJ Aging Mech Dis; 2016; 2():16026. PubMed ID: 28721276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bilateral stenosis of carotid siphon in Hutchinson-Gilford progeria syndrome.
    Narazaki R; Makimura M; Sanefuji M; Fukamachi S; Akiyoshi H; So H; Yamamura K; Doisaki S; Kojima S; Ihara K; Hara T; Ohga S
    Brain Dev; 2013 Aug; 35(7):690-3. PubMed ID: 23141186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.
    Macicior J; Marcos-Ramiro B; Ortega-Gutiérrez S
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
    Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
    FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hutchinson-Gilford Progeria Syndrome-Current Status and Prospects for Gene Therapy Treatment.
    Piekarowicz K; Machowska M; Dzianisava V; Rzepecki R
    Cells; 2019 Jan; 8(2):. PubMed ID: 30691039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.
    Kang SM; Seo S; Song EJ; Kweon O; Jo AH; Park S; Woo TG; Kim BH; Oh GT; Park BJ
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.